MA40547A - Indoles pouvant être utilisés dans l'infection par le virus influenza - Google Patents

Indoles pouvant être utilisés dans l'infection par le virus influenza

Info

Publication number
MA40547A
MA40547A MA040547A MA40547A MA40547A MA 40547 A MA40547 A MA 40547A MA 040547 A MA040547 A MA 040547A MA 40547 A MA40547 A MA 40547A MA 40547 A MA40547 A MA 40547A
Authority
MA
Morocco
Prior art keywords
indoles
influenza virus
virus infection
compounds
formula
Prior art date
Application number
MA040547A
Other languages
English (en)
Inventor
Ludwig Paul Cooymans
Werner Constant Johan Embrechts
Jérôme Emile Georges Guillemont
Tim Hugo Maria Jonckers
Gowan David Craig Mc
Antoine Benjamin Michaut
Pierre Jean-Marie Bernard Raboisson
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of MA40547A publication Critical patent/MA40547A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne des composés ayant la structure de formule (i) qui peuvent être utilisés pour le traitement des ou contre les infections par le virus influenza.
MA040547A 2014-08-08 2015-08-07 Indoles pouvant être utilisés dans l'infection par le virus influenza MA40547A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14180331 2014-08-08

Publications (1)

Publication Number Publication Date
MA40547A true MA40547A (fr) 2017-06-14

Family

ID=51298610

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040547A MA40547A (fr) 2014-08-08 2015-08-07 Indoles pouvant être utilisés dans l'infection par le virus influenza

Country Status (18)

Country Link
US (1) US10597390B2 (fr)
EP (1) EP3177609A1 (fr)
JP (1) JP6577570B2 (fr)
KR (1) KR102488479B1 (fr)
CN (1) CN106573920B (fr)
AU (1) AU2015298876B2 (fr)
BR (1) BR112017002370B1 (fr)
CA (1) CA2954751C (fr)
CL (1) CL2017000309A1 (fr)
EA (1) EA201790266A1 (fr)
IL (1) IL250408B (fr)
MA (1) MA40547A (fr)
MX (1) MX381488B (fr)
PH (1) PH12017500207A1 (fr)
SG (1) SG11201700956VA (fr)
UA (1) UA124609C2 (fr)
WO (1) WO2016020526A1 (fr)
ZA (1) ZA201700952B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20207129B (en) 2009-06-17 2020-07-10 Vertex Pharma Inhibitors of influenza viruses replication
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
EA201790266A1 (ru) 2014-08-08 2017-06-30 Янссен Сайенсиз Айрлэнд Юси Индолы для применения при инфекции, вызванной вирусом гриппа
EP3294717B1 (fr) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Procédés de préparation d'inhibiteurs de réplication des virus de la grippe
WO2016183120A1 (fr) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibiteurs de la réplication des virus de la grippe
EP3362451B1 (fr) 2015-12-09 2023-04-12 Sunshine Lake Pharma Co., Ltd. Inhibiteurs de réplication du virus de l'influenza, méthodes d'application et utilisations associées
WO2017118680A1 (fr) * 2016-01-07 2017-07-13 Janssen Sciences Ireland Uc Acides pentanoïques fonctionnalisés à utiliser dans des infections à virus influenza
WO2017133670A1 (fr) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Dérivés de pyridine et de pyrimidine et leur utilisation dans le traitement, l'atténuation des symptômes ou la prévention de la grippe
CN107759571B (zh) * 2016-08-16 2021-03-02 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
US10647693B2 (en) 2016-08-30 2020-05-12 North & South Brother Pharmacy Investment Company Limited Inhibitors of influenza virus replication, application methods and uses thereof
MX394277B (es) * 2016-09-05 2025-03-24 Guangdong Raynovent Biotech Co Ltd Derivados de pirimidina contra virus de la influenza
CA3045371C (fr) 2016-12-15 2024-05-14 Sunshine Lake Pharma Co., Ltd. Inhibiteurs de replication du virus de la grippe et utilisations associees
EP4306166A3 (fr) * 2016-12-23 2024-06-26 Aquinnah Pharmaceuticals Inc. Composés, compositions et procédés d'utilisation
WO2018127096A1 (fr) 2017-01-05 2018-07-12 Sunshine Lake Pharma Co., Ltd. Inhibiteurs de réplication du virus de la grippe et utilisations associées
US10927118B2 (en) 2017-03-02 2021-02-23 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
CN108727369B (zh) * 2017-04-25 2023-06-09 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
NZ767352A (en) * 2018-03-05 2023-05-26 Guangdong Raynovent Biotech Co Ltd Crystal form and salt form of pyridopyrazole compound and preparation method therefor
CN114127068B (zh) 2019-07-22 2024-05-28 广东众生睿创生物科技有限公司 嘧啶衍生物的优势盐型及其晶型
CN113045475A (zh) * 2019-12-27 2021-06-29 上海泓博智源医药股份有限公司 一种5-溴-7-甲基吲哚的制备方法
CA3185649A1 (fr) 2020-07-20 2022-01-27 Bakary-Barry Toure Composes indoliques utiles en tant que modulateurs du recepteur des androgenes
EP4214201A4 (fr) * 2020-09-18 2024-10-09 Sunshine Lake Pharma Co., Ltd. Procédé de préparation de composés de pyrimidine pipérazine substitués
AU2023361174A1 (en) * 2022-10-12 2025-05-01 Maze Therapeutics, Inc. Inhibitors of solute carrier family 6a member 19 (slc6a19) and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2364340T3 (es) 2004-03-30 2011-08-31 Vertex Pharmaceuticals Incorporated Azaindoles útiles como inhibidores de jak y otras proteína quinasas.
NZ592968A (en) 2006-01-17 2012-08-31 Vertex Pharma Azaindoles substituted with either triazine or pyrimidine useful as inhibitors of janus kinases consisting of JAK1, JAK2, JAK3, and TYK2
GEP20207129B (en) * 2009-06-17 2020-07-10 Vertex Pharma Inhibitors of influenza viruses replication
EP2613781B1 (fr) 2010-09-08 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Dérivés indazole à utiliser dans le traitement d'une infection par le virus de la grippe
AU2011343647A1 (en) * 2010-12-16 2013-05-02 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
RU2013132681A (ru) 2010-12-16 2015-01-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы репликации вирусов гриппа
UA118010C2 (uk) * 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
WO2013030138A1 (fr) 2011-09-01 2013-03-07 F. Hoffmann-La Roche Ag Inhibiteurs de pyrrolopyrazine kinase
WO2013184985A1 (fr) 2012-06-08 2013-12-12 Vertex Pharmaceuticals Incorporated Inhibiteurs de la réplication de virus de la grippe
PT3068776T (pt) 2013-11-13 2019-08-26 Vertex Pharma Inibidores da replicação de vírus da gripe
AR101401A1 (es) 2014-08-08 2016-12-14 Bayer Cropscience Ag Derivados de bipirazol, sustituidos con halógeno
UY36255A (es) 2014-08-08 2016-01-29 Bayer Cropscience Ag Compuestos sustituidos por halógeno novedosos
EA201790266A1 (ru) 2014-08-08 2017-06-30 Янссен Сайенсиз Айрлэнд Юси Индолы для применения при инфекции, вызванной вирусом гриппа
CN104592038A (zh) 2015-01-12 2015-05-06 烟台万润精细化工股份有限公司 一种5,5-二甲基-1,3-环己二胺的制备方法

Also Published As

Publication number Publication date
CA2954751C (fr) 2023-01-17
EP3177609A1 (fr) 2017-06-14
CL2017000309A1 (es) 2017-08-18
CN106573920A (zh) 2017-04-19
JP6577570B2 (ja) 2019-09-18
KR102488479B1 (ko) 2023-01-12
WO2016020526A1 (fr) 2016-02-11
SG11201700956VA (en) 2017-03-30
AU2015298876A1 (en) 2017-02-02
AU2015298876B2 (en) 2020-02-13
PH12017500207B1 (en) 2017-07-10
US20170226102A1 (en) 2017-08-10
IL250408A0 (en) 2017-03-30
UA124609C2 (uk) 2021-10-20
BR112017002370A2 (pt) 2017-12-05
US10597390B2 (en) 2020-03-24
EA201790266A1 (ru) 2017-06-30
MX2017001752A (es) 2018-02-08
PH12017500207A1 (en) 2017-07-10
IL250408B (en) 2020-08-31
ZA201700952B (en) 2018-12-19
CA2954751A1 (fr) 2016-02-11
CN106573920B (zh) 2020-11-10
BR112017002370B1 (pt) 2022-11-22
JP2017523225A (ja) 2017-08-17
MX381488B (es) 2025-03-12
KR20170039275A (ko) 2017-04-10

Similar Documents

Publication Publication Date Title
PH12017500207A1 (en) Indoles for use in influenza virus infection
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
MX381314B (es) Pirimidinas sustituidas con arilo para su uso en la infeccion por virus influenza
PH12016501254A1 (en) Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
HUE058737T2 (hu) Eljárások arenaviridae vírusok okozta fertõzések kezelésére
WO2015153889A3 (fr) Substances et procédés pour le traitement d'une infection virale latente
EA201692316A1 (ru) Производные холана для применения при лечении и/или профилактике fxr и tgr5/gpbar1-опосредованных заболеваний
EA201691726A1 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201790630A1 (ru) Способы получения рибозидов
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
EA202091849A1 (ru) Тиазолидные соединения для лечения вирусных инфекций
EA201791174A1 (ru) Антимикотическое соединение
EA201790517A1 (ru) Способы и композиции для индуцирования защитного иммунитета против филовирусной инфекции
UY36221A (es) Derivados de isoindolinona
MX2017004655A (es) Compuestos de hidroxil purinas y aplicaciones de estos.
EA201891576A1 (ru) Функционализированные пентановые кислоты для применения при инфекциях, вызванных вирусом гриппа
CL2017000151A1 (es) Derivados de piridona
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201690594A1 (ru) Состав для лечения вич-инфекции на основе атазанавира и кобицистата
DE112015002229A5 (de) Formulierungen zur Behandlung von Hyperthyreose
MX2017006043A (es) Metodo y composiciones de anti-hcmv.
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
MX2016009250A (es) Nuevos imidazoles para el tratamiento y profilaxis de la infeccion por virus sincicial respiratorio.